Gulf Pharmaceutical Industries

Julphar: the listed company and its business

As of: 2026-06-30

Gulf Pharmaceutical Industries JULPHAR CO Public JSC is the Ras Al Khaimah pharmaceutical issuer traded on ADX as JULPHAR. Incorporated in 1980, it began commercial activity in 1984. This profile concerns the listed parent and its consolidated subsidiaries, not a government holding company or an individual pharmacy chain. The group manufactures and sells medicines, pharmaceutical and medical compounds, alongside distribution activities. Its business combines regulated production, product development, market registrations and access to private and tender customers. Financial figures below are consolidated and expressed in AED millions unless stated otherwise; they are not parent-only accounts.

Products and routes to customers

As of: 2025-12-31 / 2026-06-30

Julphar reports more than 300 pharmaceutical products, covering diabetes, cardiovascular and respiratory conditions, anti-infectives and selected biologics. Its industrial experience includes recombinant insulin. Manufacturing earns returns through approved products, production efficiency and commercial mix; distribution adds procurement, logistics and customer access. Registrations and compliant facilities are prerequisites for market entry, not a guarantee of attractive margins. Private-market demand and tender awards create different pricing and collection conditions. The latest management report identifies the UAE, Saudi Arabia, Iraq and Morocco among the key markets for its commercial efforts. It does not disclose dependable product-level profitability or a tender backlog.

Group perimeter after disposals

As of: 2026-06-30

At June 2026, Planet Pharmacies and Mena Cool Transportation remain wholly owned subsidiaries. Planet retains UAE distribution businesses, including Julphar Drug Store and Awafi Drug Store. The UAE retail and Oman transaction companies were sold during the first half; their former revenues should not be described as continuing group operations. Julphar Pharmaceuticals in Ethiopia remains 55% owned but is classified as held for sale and discontinued: the sale had not completed at the reporting date. Its assets held for sale were AED 26.7 million. Several Egyptian, Saudi, Tunisian and Kenyan legal entities in the subsidiary schedule are explicitly marked non-operational with immaterial results. A legal presence is therefore not evidence of an operating factory or material local sales.

Shareholders and control boundaries

As of: 2025-12-31 / 2026-06-30

The dated ownership table at December 2025 lists Middle East Pharma Investments at 24.10%, the Government of Ras Al Khaimah at 12.24%, Yasser bin Youssef bin Mohammed Nagi at 9.00%, Mohammed Abdulaziz Rabee Shahin Al Mehairi at 7.58%, Shaikh Faisal bin Saqr bin Mohammed Al Qasimi at 6.49%, and ACDIMA at 6.20%. The report prints an aggregate of 65.60%; the rounded components add to 65.61%. That discrepancy is retained rather than silently corrected. These are significant shareholdings, not proof of common beneficial ownership or sole control. They are a dated snapshot, not a live shareholder register. The interim statements report 1,155,227,811 ordinary shares with AED 1 par value.

Manufacturing assets, output and investment

As of: 2025-12-31 / 2026-06-30

The annual report describes 10 accredited manufacturing facilities in Ras Al Khaimah and approximately 165 million packs produced in 2025. Output must not be equated with installed capacity or utilisation: a consistent denominator is not supplied. MenaCool's reported fleet of 40 temperature-controlled trucks supports the medicine supply chain. At June 2026, consolidated property, plant and equipment stood at AED 242.8 million, excluding separately presented assets held for sale. First-half PPE additions were AED 19.2 million. The parent factory stands on government-owned land. The Saudi manufacturing investment remains a project progressing through licensing and development work; the latest report does not establish commercial commissioning, funded total cost or a firm capacity ramp.

Geography on a comparable basis

As of: 2026-06-30 / 2025-12-31

Management's continuing-operation breakdown for the first half of 2026 reports UAE revenue of AED 240.6 million, other GCC revenue of AED 181.6 million and other-country revenue of AED 151.5 million. These sum to AED 573.7 million. Stronger GCC sales offset weakness elsewhere. The geographic table in the financial notes starts from a broader perimeter before deducting discontinued sales; mixing those regional figures with continuing revenue would misstate exposure. The annual narrative also differs on reach: its overview cites 30 countries while the governance narrative cites 40. Neither is treated here as a verified current count of active markets. Registrations, offices and revenue-generating markets are different measures.

Latest financial results and the annual baseline

As of: 2026-06-30 / 2025-12-31

The table separates the latest half-year comparison from the audited annual baseline. Half-year comparatives are the restated and re-presented figures in the latest interim statements. In 2026, stronger continuing profit coexists with lower total profit because the prior half-year contained a large disposal gain. Total profit for 2025 likewise included substantial discontinued-operation income. Total profit is therefore not a clean measure of recurring pharmaceutical earnings. Cash-flow rows cover the statutory group perimeter, including discontinued operations. Half-year results are not annualised forecasts; the annual and interim columns are distinct periods, not a sequential growth series. Parent-attributable profit is distinguished from profit including non-controlling interests.

Cash conversion and receivables

As of: 2026-06-30

Operating cash flow was negative AED 4.3 million in the first half of 2026 despite positive earnings. Receivables absorbed AED 162.4 million and inventories AED 44.4 million, partly offset by AED 104.1 million from trade payables and accruals. This makes collection and working-capital discipline central to the recovery. Gross trade receivables were AED 752.4 million with an expected-credit-loss allowance of AED 134.8 million; the reduction in the allowance partly reflects derecognition on disposal, not simply better collection. Cash equivalents in the cash-flow statement were AED 199.1 million versus AED 194.5 million on the balance sheet, because cash in assets held for sale is presented separately. Longer deposits and restricted cash must not be silently added to either definition.

Debt, liquidity and covenant limits

As of: 2026-06-30

Bank borrowings were AED 263.8 million at June 2026, unchanged from year-end after the previous year's deleveraging. The current portion was AED 15.4 million and the non-current portion AED 248.4 million; the latter matures in April 2030. Pricing is three-month EIBOR plus 2.5%. Lease liabilities are separate from these bank borrowings. The facility has security over assets and receivables and a subsidiary guarantee. Disclosed covenant thresholds include minimum equity of AED 850 million and debt/equity below 1.75; reported equity was AED 1,016.0 million. A simple comparison with the equity floor does not establish compliance with all contractual tests. Actual tested ratios and full covenant headroom are not supplied, so no clean-compliance conclusion is made.

Launches, research and sector indicators

As of: 2026-06-30

During the first half of 2026, management reports 4 new UAE products comprising 8 SKUs and 16 international registrations outside the UAE. These measure portfolio progress, not guaranteed incremental revenue. Continuing EBITDA of AED 86.8 million is management's performance measure and should not replace statutory operating profit or cash flow. Research and development expense in the interim income statement was AED 10.6 million. Useful measures to follow are launch-to-sales conversion, repeat demand, product mix, factory utilisation, expiry losses and cash collection. The selected evidence does not provide a comparable utilisation series, profitability by product or probability-weighted pipeline. No assumed market share or pharmaceutical market forecast is used to fill those gaps.

Reporting quality and governance

As of: 2025-12-31 / 2026-06-30

The annual auditor's opinion was unmodified, with an emphasis of matter about restated comparatives and inventory measurement as a key audit matter. The interim report carries a review conclusion, not an annual audit opinion. Its prior-period adjustment note reduces first-half 2025 total profit from AED 158.2 million as previously reported to AED 131.4 million. Inventory measurement, elimination of unrealised intragroup profit, refund liabilities and expense classification require attention. These adjustments matter because changes in gross margin and profit can otherwise be mistaken for purely operating improvement. Formal governance and a positive review conclusion do not remove estimation uncertainty. The latest restated comparatives control this profile; older figures are not spliced into an apparently consistent growth history.

Business risks that remain material

As of: 2025-12-31 / 2026-06-30

Medicines require consistent quality, regulatory compliance and dependable delivery. The annual report describes two precautionary recalls attributed by the company to an external supplier issue; its statement that these were unrelated to internal manufacturing failures is an issuer assertion, not an independent finding. Financial impact is not quantified in the selected disclosure. Commercial risks include slow collections, inventory expiry, tender pricing and an unfavourable product mix. Geopolitical disruption may affect export demand, raw-material availability, freight and customer payment timing. The interim note reports no significant disruption requiring balance-sheet adjustment at approval, while saying the evolving financial impact cannot be reliably estimated. That qualified assessment should not be read as immunity from regional risk.

Strategy and what would demonstrate progress

As of: 2025-12-31 / 2026-06-30

The strategic direction combines manufacturing upgrades, in-house research, selected alliances, product launches and expansion in chosen markets, including the planned Saudi facility. Disposals reduce exposure to non-core activities and simplify the business, but disposal proceeds are not recurring operating receipts. Progress should be judged by profitable sales from new registrations, reliable supply, improved collection and investment delivered within disclosed budgets and milestones. The Saudi project remains subject to execution and licensing rather than being booked here as future revenue. Sustained continuing earnings supported by cash would be more informative than another headline gain on asset sales. This is a business profile, without a price target, valuation or trading recommendation.

Official contacts and evidence dates

As of: 2026-08-31 / 2026-06-30 / 2025-12-31

The corporate address is Airport Road, Digdaga, P.O. Box 997, Ras Al Khaimah, UAE. General switchboard: +97172461461. Investor relations: investors@julphar.net. The official contact page also provides functional departmental channels; personal contact details are not reproduced here. Financial evidence runs through June 2026, with the interim statements and management discussion published on 13 August 2026. The ownership and annual operating snapshots remain dated December 2025. The official current financial-report index was checked on 31 August 2026 and listed the half-year package as its latest financial period. Sources are linked by section with physical PDF pages; referenced documents remain on the issuer's site.

Sources

1. A · Source A · 2025-12-31
2. H · Source H · 2026-06-30; published 2026-08-13
3. M · Source M · 2026-06-30; published 2026-08-13
4. C · Source C · 2026-08-31
5. I · Source I · 2026-08-31